This month, the UK Medicines & Healthcare products Regulatory Agency released for public consultation its new licensing pathway for biosimilars that is set to apply from the start of 2021. (Also see "UK Lays Out Reduced-Data Pathway For Biosimilars" - Generics Bulletin, 9 October, 2020.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?